ISP-TACE Versus TACE for HCC With PVTT

Southeast University

Status: Completed

Conditions: Portal Vein Tumor Thrombosis; HCC

Treatments: Drug: ethiodized oil; doxorubicin;Gelfoam;; Device: stent; idoine-125

Study type: Observational

Funder types: Other

Identifiers

NCT03108248

ZhongdaHP

Details and patient eligibility

About

For patients with advanced hepatocellular carcinoma (HCC) and portal vein tumor thrombosis (PVTT), the survival benefit of transarterial chemoembolization (TACE) remains modest. This study aimed to investigate whether TACE in combination with irradiation stent placement (ISP) could prolong the survival in patients with HCC and PVTT.

Enrollment: 126 patients

Sex: All

Ages: 20 to 75 years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• (1) newly diagnosed HCC with type II or III PVTT, (2) Child-Pugh classification grade A or B, (3) Eastern Cooperative Oncology Group (ECOG) performance status score 0-2.

Exclusion criteria

• (1) type I or IV PVTT, (2) received sorafenib, systemic chemotherapy, or external radiotherapy during the treatment, (3) suffered from malignancy other than HCC, (4) with an incomplete data.

Trial design

126 participants in 2 patient groups

ISP-TACE group

Description:

During the study period, a total of 44 patients with HCC with PVTT underwent the irradiation stent placement and TACE were included in the ISP-TACE group.

Treatment:

Drug: ethiodized oil; doxorubicin;Gelfoam;

TACE group

Description:

During the study period, a total of 82 patients with HCC with PVTT underwent TACE monotherapy were included in the ISP-TACE group.

Treatment:

Drug: ethiodized oil; doxorubicin;Gelfoam;

Device: stent; idoine-125